MT-125 treatment for recurrent high-grade brain tumors
Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas
Adults with recurrent high-grade gliomas will receive the brain-penetrant drug MT-125 to find safe doses and check whether it can slow tumor invasion and growth.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Myosin Therapeutics INC. NIH-funded |
| Lab location | 1 site (Jupiter, United States) |
| Project ID | NIH-11174970 on NIH RePORTER |
What this research studies
This early-phase dose-escalation trial gives MT-125 alone to adults with recurrent high-grade gliomas to identify the safest and brain-penetrant dose. Participants will have regular clinic visits, blood tests, brain imaging, and possible tumor sampling to track side effects, drug levels in the brain, and signs that tumors stop invading or dividing. Doses are increased carefully in small groups to find dose-limiting toxicities and the recommended dose for future trials, and results will be compared with preclinical data showing MT-125 blocks both invasion and proliferation.
Who could benefit from this research
Good fit: Adults with recurrent high-grade gliomas (including glioblastoma) who meet the trial's health and prior-treatment criteria and can travel to the study site would be ideal candidates.
Not a fit: People with low-grade brain tumors, newly diagnosed glioblastoma who have not completed initial standard therapy, serious competing medical conditions, or inability to attend site visits are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, MT-125 could slow tumor invasion and growth and potentially extend survival for people with recurrent high-grade gliomas.
How similar studies have performed: Preclinical lab and animal studies show MT-125 can block both invasion and proliferation and extend survival, but this is an early human trial and similar NMII-targeting drugs have not yet been proven effective in patients.
Where this research is happening
Jupiter, United States
- Myosin Therapeutics INC. — Jupiter, United States (Active)
Researchers
- Principal investigator: Brownstein, Michael J — Myosin Therapeutics INC.
- Study coordinator: Brownstein, Michael J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.